• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Pharmaceutical Sciences Review and Research >Development and Characterization of Enclosed Prochlorperazine Maleate Floating Alginate Beads
【24h】

Development and Characterization of Enclosed Prochlorperazine Maleate Floating Alginate Beads

机译：封闭盆种Maleate浮藻酸盐珠的开发和表征

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of present study aims to formulate enclosed floating alginate beads of Prochlorperazine Maleate (PCZM) for the treatment of nausea and vomiting. The Prochlorperazine Maleate which is having lower bioavailability up to 12.5% and also, it’s a lower biological half-life so which required multiple dosing frequencies 3-4 times a day. Bioavailability refers that to extend and rate at which the active moiety enters into the systemic circulation to the site of action. Biological half-life is the time that a body requires to eliminate one-half the quantity of an administered substance. So, by using Floating Alginate Beads of Prochlorperazine maleate which is help to Produced sustained released action up to 12 hours. Hence, it helpful for improvement of bioavailability and biological half-life, and reduced frequency of dosing. The Prochlorperazine Maleate (PCZM) beads were formulated by the Ionotropic gelation method by sodium alginate solution containing Low methylated pectin in various ratios. The Preformulation study was performed like Physical characters, Drug Excipients compatibility study by Calibration curve, FTIR and DSC study. The floating alginate beads were evaluated by different parameters like Percentage yield, Drug Content (DC) & Entrapment Efficiency (EE), In-vitro Drug Release study, particle size analysis, Z-Potential, SEM, PXRD, Stability study. The result of the FT-IR and DSC study indicated the stability and compatibility of the drug & polymers. The standard calibration curve in 0.1 N HCl (pH 1.2) showed a regression of 0.999. The percentage yield was found to be 86.29% to 95.90%. The drug content was found to be 3.7- 4.7 mg. The percentage buoyancy was found to be 89.40% to 97.50%. The in-vitro drug release study of the formulated batch was ranged from 77.29% to 91.44% at the end of 12 h. The best formulation was selected as batch B-2 which gives the best result based on Percentage Yield, DC, EE, buoyancy study, and In-vitro Drug Released study. Particle size observed in Nano range that is 393.3 nm and, Z-potential found to be -2.84mV. By Scanning Electron Microscopy (SEM) the beads were shown to be Spherical and slightly rough surface because of drying. A powdered X-Ray Diffraction study showed that the drug is converted from crystalline to an amorphous form. The B 2 Optimized batch drug content was found to be 4.62 mg and it is having no change in its physical appearance. Hence it shows good stability up to 60th day.
机译：目前研究的目的旨在配制封闭的浮动藻酸盐珠珠珠酮（PCZM），用于治疗恶心和呕吐。普罗氯嗪马来酸盐，其生物利​​用度降低至12.5％，而且还具有较低的生物半衰期，从而需要每天3-4次的多剂量频率。生物利用度是指延伸和速率，活性部分进入到行动部位的系统循环中。生物半衰期是身体所需的时间来消除施用物质的一半的时间。因此，通过使用Prochorlazine Maleate的浮藻酸盐珠子，有助于产生长达12小时的缓释释放作用。因此，它有助于改善生物利用度和生物半衰期，减少给药频率。通过含有低甲基化果胶的离子酸钠凝胶法配制促氯吡嗪（PCZM）珠子，其各种比例含有低甲基化果胶。预先形成研究如物理特征，药物赋形剂通过校准曲线，FTIR和DSC研究进行兼容性研究。通过不同的参数评估浮藻酸盐珠粒，如百分比产量，药物含量（DC）＆amp;血管效率（EE），体外药物释放研究，粒度分析，Z电位，SEM，PXRD，稳定性研究。 FT-IR和DSC研究的结果表明了药物稳定性和兼容性;聚合物。 0.1n HCl（pH 1.2）中的标准校准曲线显示出0.999的回归。发现产量百分比为86.29％至95.90％。发现药物含量为3.7-4.7mg。发现浮力百分比为89.40％至97.50％。配制批料的体外药物释放研究在12小时的末端的范围为77.29％至91.44％。选择最佳的配方作为分批B-2，其基于产量，DC，EE，浮力研究和体外药物释放研究的百分比产生了最佳结果。在纳米范围内观察到393.3nm的粒度，Z-电位为-2.84mV。通过扫描电子显微镜（SEM），由于干燥而显示珠子是球形和略微粗糙的表面。粉末X射线衍射研究表明，该药物由结晶转化为无定形形式。发现B 2优化的分批药物含量为4.62mg，其物理外观没有变化。因此，它显示出良好的稳定性至第60天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号